ADCs revolutionize breast cancer care, expanding beyond HER2-positive to HER2-low tumors, reshaping early therapy—and spotlighting MRD testing as the next frontier.
The OncoloGIST
EP. 2: Lung Cancer Treatment Is Changing Fast — Here's What Doctors Learned at the 2026 TTLC Meeting
Estelamari Rodriguez, MD, delivers her top takeaways from the 2026 IASLC Targeted Therapies in Lung Cancer meeting.
Experts from Memorial Sloan Kettering Cancer Center discuss updates from the 2026 European Lung Cancer Congress.
MSK experts discuss FLAURA2 updates, emerging targets in mesothelioma, and next-gen immunotherapies from the 2026 European Lung Cancer Congress.
Dr Christine Bestvina discusses EGFR treatment shifts, expanding community clinical trial access, and upcoming KRAS G12C and neoadjuvant therapy data.